Talis Biomedical Corporation (NASDAQ:TLIS) previous close was $10.05 while the outstanding shares total 23.48M. TLIS’s shares traded higher over the last trading session, gaining 5.47% on 06/09/21. The shares fell to a low of $9.71 before closing at $10.60. Intraday shares traded counted 0.75 million, which was -268.49% lower than its 30-day average trading volume of 203.22K. The stock’s Relative Strength Index (RSI) is 47.56, with weekly volatility at 11.39% and ATR at 0.90. The TLIS stock’s 52-week price range has touched low of $9.43 and a $33.90 high.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Investors have identified the Medical Devices company Talis Biomedical Corporation as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $267.23 million, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
Talis Biomedical Corporation (TLIS) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. In terms of their assets, the company currently has 391.32 million total, with 46.85 million as their total liabilities.
TLIS were able to record -23.18 million as free cash flow during the 09/01/2021 quarter of the year, this saw their quarterly net cash flow reduce by 210.3 million. In cash movements, the company had a total of -22.48 million as operating cash flow.
Potential earnings growth for Talis Biomedical Corporation (TLIS)
What matters though is how it ends. When the core data for the company is broken down, then the stock sounds interesting. The company spent 7.0 million trying to sell their products during the last quarter, with the result yielding a gross income of 67.52 million. This allows shareholders to hold on to 23.48M with the recently reported earning now reading -4.61 cents per share. This is a figure that compared to analyst’s prediction for their 09/01/2021 (-4.61 cents a share).
Having a look at the company’s valuation, the company is expected to record -1.11 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on TLIS sounds very interesting.
Is the stock of TLIS attractive?
In related news, Director, Scott Randal W. bought 11,000 shares of the company’s stock in a transaction that recorded on May 17. The purchase was performed at an average price of 10.11, for a total value of 111,210. As the purchase deal closes, the Director, Scott Randal W. now bought 9,000 shares of the company’s stock, valued at 91,440. Also, Sr. Vice President, R&D, Ramakrishnan Ramesh bought 1,000 shares of the company’s stock in a deal that was recorded on Feb 17. The shares were cost at an average price of 16.00 per share, with a total market value of 16,000. Following this completion of disposal, the Director, Posard Matthew L. now holds 62,500 shares of the company’s stock, valued at 1,000,000. In the last 6 months, insiders have changed their ownership in shares of company stock by 1.20%.
3 out of 4 analysts covering the stock have rated it a Buy, while 1 have maintained a Hold recommendation on Talis Biomedical Corporation. 0 analysts has assigned a Sell rating on the TLIS stock. The 12-month mean consensus price target for the company’s shares has been set at $14.00.
